Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, Phase I/II trial to determine the safety of RAD001 in
combination with docetaxel and compare the efficacy of RAD001 plus docetaxel versus published
Phase II and III reports of docetaxel alone in patients with recurrent NSCLC.